CD274 and hereditary clear cell renal cell carcinoma: To further discuss the relationship between PECMS and the response to ICB therapy, we introduced an independent cohort (IMvigor-210) in which renal cell carcinoma patients were treated with ICB (atezolizumab, an anti-PD-L1 antibody).